Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > MC Cap the same

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 03, 2021 11:19am

154 Views

Post# 33318904

RE:RE:RE:MC Cap the same

Right ! I year since P2B results were posted.

Now we wait for a catalyst - hoping the amalgamation takes negotiations to the next level.

Based on the China deal alone, I would expect a minimum of ...
$529M from a USA partner
$176M from a European partner
$83.5M from a Japan partner.

A Japan deal could be higher if it covers additional geographies.

So ... $789M in milestone agreements plus royalties (minimum) would be expected.
Something like that could net us more than $150M upfront.

Certainly, the longer we go, the more we could expect. I do think we're already past this pricing but it's just a reference point w.r.t. the China deal.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program